MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Neuroprotective and neurotrophic efficacy of Ginkgo biloba extracts against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease

    P. Kashyap, S. Gupta (Darbhanga, India)

    Objective: The present study examined the potential neuroprotective and neurotrophic efficacy of GBE against 3-nitropropionic acid (3-NP)-induced oxidative stress in a rat model of HD…
  • 2019 International Congress

    Huntington’s Disease Protein Huntingtin Associates with its own mRNA

    M. Rakhimova, M. Daropova (Tashkent, Uzbekistan)

    Objective: To investigate how Htt might affect RNA metabolism we set out to purify and analyze RNA associated with Htt. Background: The Huntington's disease (HD)…
  • 2019 International Congress

    Assessment of Caregiver Burden in Huntington’s disease

    M. Yu, K. Tan, K. Koloms, D. Bega (Chicago, IL, USA)

    Objective: We aim to identify and characterize caregiver burden among HD caregivers, to see what aspects of HD caregiving are associated with the greatest burden…
  • 2019 International Congress

    Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients

    C. Cattaneo, E. Bonizzoni, C. Keywood (Milan, Italy)

    Objective: To evaluate the clinical effects of safinamide, administered as add-on therapy to levodopa in fluctuating PD patients, on symptoms severity and daily living. Background:…
  • 2019 International Congress

    Switching entacapone ‘non-responders’ to open-label opicapone: change in absolute OFF-time following the 1-year extension BIPARK-I study

    J. Ferreira, A. Lees, W. Poewe, O. Rascol, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) ‘non-responders’ patients who switched from placebo (PLC) or entacapone (ENT) to OPC…
  • 2019 International Congress

    The Effect of Gocovri on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program

    R. Hauser, D. Kremens, D. Chernick, R. Patni, J. Hubble (Tampa, FL, USA)

    Objective: To assess the impact of Gocovri® (amantadine) extended release capsules on motor aspects of experiences of daily living in PD patients. Background: Gocovri is…
  • 2019 International Congress

    Pharmacological effect of adenosine A2A receptor antagonist for levodopa-induced dyskinesia associated with cellular energy homeostasis

    NAO. Kanzato (Okinawa, Japan)

    Objective: To evaluate the Levodopa induced dyskinesia (LID) in the clinical view point of autophagy and cellular energy homeostasis, and the pharmacological effect of adenosine…
  • 2019 International Congress

    Use digital sensor and deep learning to evaluate motor performance in the D1PAM (LY3154207) phase 1B Parkinson’s disease clinical trial

    Y. Li, Y. Guan, J. Wang, A. Calvin, J. Kyle, B. Miller (Indianapolis, IN, USA)

    Objective: This study aims to test the feasibility of using digital tools to evaluate motor performance in a Parkinson’s disease clinical trial. Background: Modern smartphones…
  • 2019 International Congress

    Efficacy and Safety of the 5-Hydroxytryptophan on REM Sleep Behavior Disorder in Parkinson’s Disease.

    M. Meloni, M. Figorilli, M. Carta, L. Tamburrino, A. Cannas, M. Fantini, G. Defazio, M. Puligheddu (Cagliari, Italy)

    Objective: To evaluate the efficacy of the 5-HTP on RBD status in patients with Parkinson's disease (PD). Background: REM sleep behavior disorder (RBD) is reported…
  • 2019 International Congress

    The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program

    R. Pahwa, C. Tanner, L. Zhang, R. Johnson, C. Leroue, R. Patni (Kansas City, KS, USA)

    Objective: To assess patient outcomes and adverse events in Parkinson’s disease (PD) patients treated with Gocovri® (amantadine) extended release capsules at bedtime for dyskinesia, by…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley